Investment Thesis
Semnur Pharmaceuticals is in critical financial distress with negative stockholders' equity of -$20.8M, indicating technical insolvency. The company is burning $5.9M annually in operating cash while holding only $20K cash, creating immediate solvency risk. Operating margins of -320.8% and a liquidity ratio of 0.06x reflect a fundamental business model failure with high bankruptcy risk.
Strengths
- Maintains $50M revenue base despite operational crisis
- Operating in pharmaceutical sector with structural market demand
- Still has debt capacity theoretically if capital restructuring possible
Risks
- Negative stockholders' equity of -$20.8M indicates balance sheet insolvency
- Cash position of $20K cannot sustain $5.9M annual burn rate
- Current ratio of 0.06x reflects critical liquidity crisis and inability to meet obligations
- Operating margins of -320.8% indicate severe operational dysfunction or catastrophic loss event
- Negative interest coverage ratio means zero debt servicing capability from operations
- 3320% YoY deterioration suggests major impairment, restructuring charge, or operational collapse
Key Metrics to Watch
- Remaining cash runway and monthly burn rate trajectory
- Emergency capital raise or debt restructuring announcements
- Path to positive operating income and cash flow generation
- Total liabilities reduction or debt forgiveness negotiations
- Stockholders' equity recovery to positive territory
Financial Metrics
Revenue
50.0M
Net Income
-160.4M
EPS (Diluted)
$-0.78
Free Cash Flow
-5.9M
Total Assets
1.3M
Cash
20.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-320.8%
Net Margin
-320.8%
ROE
N/A
ROA
-11,918.0%
FCF Margin
-11.7%
Balance Sheet & Liquidity
Current Ratio
0.06x
Quick Ratio
0.06x
Debt/Equity
N/A
Debt/Assets
1,641.6%
Interest Coverage
-2,899.84x
Long-term Debt
6.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T03:48:23.396239 |
Data as of: 2025-12-31 |
Powered by Claude AI